Pharmacytimes: Condition Center: Acute Coronary Syndrome Acute Coronary Syndrome en-us Thu, 30 Jul 2015 04:12:34 UTC Thu, 30 Jul 2015 04:12:34 UTC Novel Antiplatelet Agents: Clarifying Roles in ACS Acute coronary syndrome can take a variety of forms. Wed, 08 Jul 2015 04:25:00 UTC Medication Adherence After ACS Slightly Improving Studies have reported that up to half of patients discontinue prescribed therapies soon after hospital discharge. Thu, 25 Jun 2015 03:28:00 UTC How Pharmacists Can Help Manage ACS in the Elderly Acute coronary syndrome is clearly a problem in the elderly population, especially since survival declines with increasing age. Sat, 06 Jun 2015 05:00:00 UTC Half of ACS Patients Don’t Adhere to Antiplatelet Agents After Angioplasty Despite being told the importance of medication adherence, about half of acute coronary syndrome patients don’t take their oral antiplatelet therapy as prescribed. Wed, 06 May 2015 02:34:00 UTC Brilinta Granted FDA Priority Review for New Use The FDA has granted priority review to expand the use of AstraZeneca’s ticagrelor (Brilinta). Tue, 05 May 2015 04:14:00 UTC Revised ACS Guideline: Practice Points for Pharmacists Pharmacists who work with ACS patients should get familiar with this latest guideline. Mon, 13 Apr 2015 03:00:00 UTC Crushing Now Allowed for Antiplatelet Agent The FDA today approved a new administration option for ticagrelor (Brilinta). Mon, 30 Mar 2015 04:54:00 UTC Adherence to Guidelines Doesn’t Ensure ACS Inpatient Safety Many regulatory and professional organizations monitor hospitals for compliance to treatment guidelines, equating the use of evidence-based processes to high-quality care. Wed, 11 Mar 2015 03:00:00 UTC Room for Improvement in Acute Coronary Syndrome Treatment Antithrombotic therapy is an essential element of treatment after patients experience acute coronary syndrome. Fortunately, prescribers can draw from a considerably larger selection of antithrombotics than ever before, as prasugrel, ticagrelor, fondaparinux, and bivalirudin have joined warfarin, unfractionated heparin, and the low molecular weight heparins in evidence-based guidelines. Thu, 15 Jan 2015 02:00:55 UTC AstraZeneca Antiplatelet Drug Prevents Cardiovascular Events After Heart Attack AstraZeneca announced today that a study evaluating ticagrelor (Brilinta) for the secondary prevention of atherothrombotic events in patients with a history of heart attacks has met its primary efficacy endpoint. Wed, 14 Jan 2015 06:23:01 UTC Women with Celiac Disease Shouldn’t Fret Over Fertility Women with celiac disease do not report more fertility problems than the general population. Tue, 09 Dec 2014 02:00:37 UTC Reducing Acute Coronary Syndrome Readmission Rates Joe Moose, PharmD, of Moose Pharmacy, discusses the role of the pharmacist in prevention and reducing readmissions among acute coronary syndrome patients. Sat, 06 Dec 2014 06:00:57 UTC Acute Coronary Syndrome in Women: A 10-Year Review As pharmacists’ ability to tease out more comprehensive information from clinical trials has increased, it has become evident that social and biologic factors interact to produce paradoxical health differences between men and women, especially on cardiovascular outcomes. Sat, 06 Dec 2014 02:02:01 UTC Readmission Rates for Acute Coronary Syndrome Joe Moose, PharmD, of Moose Pharmacy, discusses rising readmission rates among patients with acute coronary syndrome. Fri, 05 Dec 2014 05:57:48 UTC Can Polypills Better Prevent Cardiovascular Disease? The pros and cons of fixed-dose combination therapy first became major media news in 2001 when a World Health Organization expert panel proposed polypill use for noncommunicable diseases. Fri, 28 Nov 2014 03:01:01 UTC Predicting Poor Outcomes in Myocardial Infarction Researchers identify a potential marker for poor prognosis after acute myocardial infarction. Thu, 06 Nov 2014 05:03:01 UTC Selecting Antiplatelet Agents for Diabetics With Acute Coronary Syndrome Many cardiologists and pharmacists are concerned about clopidogrel, especially when it is prescribed for patients with diabetes. Fri, 17 Oct 2014 01:16:43 UTC Starting Statins Soon After Acute Coronary Syndrome Leads to Less Unstable Angina Patients who receive statins soon after acute coronary syndrome are 24% less likely to experience unstable angina after 4 months. Thu, 11 Sep 2014 12:14:01 UTC Statins After ACS: Continue Therapy for at Least 5 Years Patients continue to benefit from high-dose atorvastatin therapy for at least 5 years after acute coronary syndrome, according to a new study. Tue, 19 Aug 2014 08:15:49 UTC Acute Coronary Syndrome: The Sad Facts in Black and White Study finds that black patients who visit the emergency department with ACS have more symptoms and higher symptom severity than white patients. Thu, 24 Jul 2014 01:03:45 UTC